|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
ES2096590T3
(es)
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
Reactivos biespecificos para la terapia del sida.
|
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
|
CA2090126C
(en)
|
1990-08-02 |
2002-10-22 |
John W. Schrader |
Methods for the production of proteins with a desired function
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1992020373A1
(en)
|
1991-05-14 |
1992-11-26 |
Repligen Corporation |
Heteroconjugate antibodies for treatment of hiv infection
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
CA2140280A1
(en)
|
1992-08-17 |
1994-03-03 |
Avi J. Ashkenazi |
Bispecific immunoadhesins
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
DE19544393A1
(de)
|
1995-11-15 |
1997-05-22 |
Hoechst Schering Agrevo Gmbh |
Synergistische herbizide Mischungen
|
|
AU2002210383A1
(en)
|
2000-10-16 |
2002-04-29 |
Proteopharma Aps |
The function of a haptoglobin-haemoglobin receptor and the uses thereof
|
|
AU2003243058A1
(en)
*
|
2002-05-27 |
2003-12-12 |
Bioceros B.V. |
Methods for using the cd163 pathway for modulating an immune response
|
|
EP1367393A1
(en)
*
|
2002-05-27 |
2003-12-03 |
MacroZyme B.V. |
Methods for using the CD 163 pathway for modulating an immune response
|
|
EP1588166A4
(en)
|
2003-01-09 |
2007-06-27 |
Macrogenics Inc |
VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
US8053569B2
(en)
|
2005-10-07 |
2011-11-08 |
Armagen Technologies, Inc. |
Nucleic acids encoding and methods of producing fusion proteins
|
|
GB0917044D0
(en)
*
|
2009-09-29 |
2009-11-18 |
Cytoguide As |
Agents, uses and methods
|
|
CA2780221A1
(en)
*
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
|
SMT201800552T1
(it)
|
2010-01-06 |
2018-11-09 |
Dyax Corp |
Proteine che legano la callicreina plasmatica
|
|
EP2632955A1
(en)
*
|
2010-10-26 |
2013-09-04 |
Technion Research & Development Foundation Ltd. |
Antibodies which bind soluble t-cell receptor ligands
|
|
KR102320178B1
(ko)
|
2011-01-06 |
2021-11-02 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 결합 단백질
|
|
WO2013008171A1
(en)
|
2011-07-11 |
2013-01-17 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to ox40 and their uses
|
|
EP4151658A1
(en)
|
2012-05-07 |
2023-03-22 |
Elasmogen Limited |
Single domain binding molecule
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
WO2014117220A1
(en)
|
2013-02-01 |
2014-08-07 |
Transbio Ltd |
Anti-cd83 antibodies and use thereof
|
|
US10519251B2
(en)
|
2013-12-30 |
2019-12-31 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
PE20170441A1
(es)
|
2014-06-06 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
|
|
US9914777B2
(en)
|
2015-07-10 |
2018-03-13 |
Merus N.V. |
Human CD3 binding antibody
|
|
TW201713690A
(zh)
|
2015-08-07 |
2017-04-16 |
再生元醫藥公司 |
抗ａｎｇｐｔｌ８抗體及其用途
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
KR101787485B1
(ko)
*
|
2015-12-30 |
2017-11-15 |
재단법인 의약바이오컨버젼스연구단 |
재조합 picp 단백질 및 이에 특이적으로 결합하는 항체의 제조방법
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
EP3448427A1
(en)
|
2016-04-29 |
2019-03-06 |
CureVac AG |
Rna encoding an antibody
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
WO2018019990A1
(en)
*
|
2016-07-28 |
2018-02-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
|
EA201991203A1
(ru)
|
2016-11-17 |
2019-10-31 |
|
Способы лечения ожирения антителами к angptl8
|
|
CA3043263A1
(en)
|
2016-11-17 |
2018-05-24 |
Innovative Targeting Solutions Inc. |
Chimeric receptors, biosensor host cells and methods/uses thereof
|
|
US20190336615A1
(en)
|
2017-01-27 |
2019-11-07 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
WO2019126194A1
(en)
|
2017-12-18 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
Angptl8 assay and uses thereof
|
|
US11773171B2
(en)
|
2017-12-19 |
2023-10-03 |
Surrozen Operating, Inc. |
WNT surrogate molecules and uses thereof
|
|
SG10201801219VA
(en)
|
2018-02-13 |
2019-09-27 |
Agency Science Tech & Res |
Anti-HER2 Antibodies
|
|
TWI857959B
(zh)
|
2018-06-26 |
2024-10-11 |
日商協和麒麟股份有限公司 |
與細胞黏著分子3 結合之抗體
|
|
WO2020018434A1
(en)
|
2018-07-17 |
2020-01-23 |
Scripps Health |
Compositions and methods for disrupting a macrophage network
|
|
EP3853251A1
(en)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
CN114423787B
(zh)
|
2019-07-19 |
2025-01-24 |
昂科里斯庞斯公司 |
免疫调节性抗体及其使用方法
|
|
WO2023034963A2
(en)
|
2021-09-03 |
2023-03-09 |
Oncoresponse, Inc. |
Combinations of immunotherapies and uses thereof
|